

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CStone Pharmaceuticals
基石藥業

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

SUSPENSION OF TRADING IN SHARES

Reference is made to the announcement of CStone Pharmaceuticals (the “**Company**”) dated March 23, 2022 in relation to, among other things, the delay in publication of annual results announcement of the Company for the year ended December 31, 2021 (the “**2021 Annual Results**”).

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited will be suspended from 9:00 a.m. on Friday, April 1, 2022, pending completion of the Investigation as announced on March 23, 2022 and the publication of the 2021 Annual Results.

By Order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Suzhou, the People’s Republic of China, April 1, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and executive director, Dr. Wei Li, Mr. Kenneth Walton Hitchner III, Mr. Yanling Cao, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.